GlassScriptPhysician profile
Pauline Watson
NPI 1619147253
$6,840.08
in general payments reported to CMS, 2019-2025
32 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $1,460 · 2021: $179 · 2022: $345 · 2023: $1,906 · 2024: $516 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,436 · Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,435.69 |
| Food and Beverage | $1,626.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,815.78 | 2023-2025 | Pascal, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $1,317.56 | 2025 | Linq II |
| Boston Scientific Corporation | $1,229.62 | 2019-2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $359.09 | 2019-2025 | |
| Pfizer INC. | $314.80 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $205.47 | 2020-2025 | Camzyos, Eliquis |
| Amgen INC. | $195.39 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $178.85 | 2019-2020 | |
| Abbott Laboratories | $134.01 | 2019-2024 | Cardiomems |
| Abiomed | $133.35 | 2023-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.77 | 2019-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $89.74 | 2019-2025 | Uptravi, Opsumit |
| Philips North America LLC | $84.95 | 2022-2024 | (5044) Mcot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.11 | 2019-2022 | |
| Astellas Pharma US INC | $72.33 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $58.01 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $46.92 | 2023-2024 | Assure Wcd |
| Ge Healthcare | $45.89 | 2020 | |
| Merck Sharp & Dohme LLC | $43.20 | 2021-2023 | Verquvo |
| Angiodynamics, INC. | $38.83 | 2024 | Alphavac |
| Lundbeck LLC | $35.22 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $32.90 | 2019-2020 | |
| Shockwave Medical, INC | $32.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.55 | 2019-2024 | |
| Siemens Medical Solutions USA, INC. | $26.19 | 2022-2024 | Acuson Origin Diagnostic Ultrasound System |
| Amarin Pharma, INC. | $22.71 | 2021 | |
| Scpharmaceuticals INC. | $18.42 | 2025 | |
| Medicomp INC | $18.10 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $15.60 | 2023 | Arcalyst |
| Medtronic Vascular, INC. | $14.55 | 2020 | |
| Irhythm Technologies, INC. | $13.99 | 2019 | |
| Cardiva Medical, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pauline Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.